Studies Coordinating Centre, Research Unit Hypertension and Cardiovascular Epidemiology, KU Leuven Department of Cardiovascular Sciences, University of Leuven, Leuven, Belgium.
Center for Epidemiological Studies and Clinical Trials and Center for Vascular Evaluations, Shanghai Institute of Hypertension, Shanghai Key Laboratory of Hypertension, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China.
PLoS One. 2018 Sep 24;13(9):e0204439. doi: 10.1371/journal.pone.0204439. eCollection 2018.
Heart transplant (HTx) recipients have a high heart rate (HR), because of graft denervation and are frequently started on β-blockade (BB). We assessed whether BB and HR post HTx are associated with a specific urinary proteomic signature.
In 336 HTx patients (mean age, 56.8 years; 22.3% women), we analyzed cross-sectional data obtained 7.3 years (median) after HTx. We recorded medication use, measured HR during right heart catheterization, and applied capillary electrophoresis coupled with mass spectrometry to determine the multidimensional urinary classifiers HF1 and HF2 (known to be associated with left ventricular dysfunction), ACSP75 (acute coronary syndrome) and CKD273 (renal dysfunction) and 48 sequenced urinary peptides revealing the parental proteins.
In adjusted analyses, HF1, HF2 and CKD273 (p ≤ 0.024) were higher in BB users than non-users with a similar trend for ACSP75 (p = 0.06). Patients started on BB within 1 year after HTx and non-users had similar HF1 and HF2 levels (p ≥ 0.098), whereas starting BB later was associated with higher HF1 and HF2 compared with non-users (p ≤ 0.014). There were no differences in the urinary biomarkers (p ≥ 0.27) according to HR. BB use was associated with higher urinary levels of collagen II and III fragments and non-use with higher levels of collagen I fragments.
BB use, but not HR, is associated with a urinary proteomic signature that is usually associated with worse outcome, because unhealthier conditions probably lead to initiation of BB. Starting BB early after HTx surgery might be beneficial.
心脏移植(HTx)受者由于供体去神经支配,心率(HR)较高,并且经常开始使用β受体阻滞剂(BB)。我们评估了 HTx 后 BB 和 HR 是否与特定的尿蛋白质组特征相关。
在 336 例 HTx 患者(平均年龄 56.8 岁;22.3%为女性)中,我们分析了 HTx 后 7.3 年(中位数)获得的横断面数据。我们记录了药物使用情况,在右心导管检查期间测量了 HR,并应用毛细管电泳与质谱联用技术来确定多维尿分类器 HF1 和 HF2(已知与左心室功能障碍相关)、ACSP75(急性冠状动脉综合征)和 CKD273(肾功能障碍)以及 48 个揭示母体蛋白的测序尿肽。
在调整后的分析中,BB 使用者的 HF1、HF2 和 CKD273(p≤0.024)高于非使用者,ACSP75 也有类似趋势(p=0.06)。HTx 后 1 年内开始使用 BB 的患者与非使用者的 HF1 和 HF2 水平相似(p≥0.098),而较晚开始使用 BB 与非使用者相比,HF1 和 HF2 水平较高(p≤0.014)。根据 HR,尿生物标志物没有差异(p≥0.27)。BB 使用与较高的尿胶原 II 和 III 片段水平相关,而非使用与较高的胶原 I 片段水平相关。
BB 使用与通常与较差预后相关的尿蛋白质组特征相关,而不是 HR,因为更不健康的状况可能导致 BB 的使用。HTx 手术后早期开始使用 BB 可能是有益的。